BNP Paribas Financial Markets’s Evolent Health EVH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.03M | Buy |
891,403
+347,019
| +64% | +$1.1M | ﹤0.01% | 2649 |
|
|
2025
Q4 | $2.18M | Buy |
544,384
+336,495
| +162% | +$1.87M | ﹤0.01% | 2561 |
|
|
2025
Q3 | $1.76M | Buy |
207,889
+196,315
| +1,696% | +$1.91M | ﹤0.01% | 2701 |
|
|
2025
Q2 | $130K | Buy |
11,574
+3,229
| +39% | +$29.7K | ﹤0.01% | 3923 |
|
|
2025
Q1 | $79K | Sell |
8,345
-29,980
| -78% | -$303K | ﹤0.01% | 4128 |
|
|
2024
Q4 | $431K | Buy |
38,325
+12,856
| +50% | +$226K | ﹤0.01% | 3388 |
|
|
2024
Q3 | $720K | Buy |
25,469
+15,299
| +150% | +$394K | ﹤0.01% | 2687 |
|
|
2024
Q2 | $194K | Sell |
10,170
-88,956
| -90% | -$2.27M | ﹤0.01% | 3110 |
|
|
2024
Q1 | $3.25M | Buy |
99,126
+46,024
| +87% | +$1.47M | ﹤0.01% | 1747 |
|
|
2023
Q4 | $1.75M | Sell |
53,102
-70,923
| -57% | -$2.01M | ﹤0.01% | 2049 |
|
|
2023
Q3 | $3.38M | Buy |
124,025
+65,671
| +113% | +$1.83M | ﹤0.01% | 1543 |
|
|
2023
Q2 | $1.77M | Buy |
58,354
+11,355
| +24% | +$367K | ﹤0.01% | 1827 |
|
|
2023
Q1 | $1.53M | Buy |
46,999
+19,767
| +73% | +$625K | ﹤0.01% | 2017 |
|
|
2022
Q4 | $765K | Sell |
27,232
-138,711
| -84% | -$3.98M | ﹤0.01% | 2320 |
|
|
2022
Q3 | $5.96M | Buy |
165,943
+143,943
| +654% | +$5.07M | 0.01% | 1277 |
|
|
2022
Q2 | $676K | Buy |
22,000
+10,524
| +92% | +$307K | ﹤0.01% | 2476 |
|
|
2022
Q1 | $371K | Sell |
11,476
-16,189
| -59% | -$424K | ﹤0.01% | 2894 |
|
|
2021
Q4 | $765K | Buy |
27,665
+8,976
| +48% | +$257K | ﹤0.01% | 2773 |
|
|
2021
Q3 | $579K | Buy |
18,689
+12,687
| +211% | +$305K | ﹤0.01% | 2677 |
|
|
2021
Q2 | $127K | Sell |
6,002
-22,586
| -79% | -$452K | ﹤0.01% | 2974 |
|
|
2021
Q1 | $577K | Buy |
28,588
+13,917
| +95% | +$265K | ﹤0.01% | 2494 |
|
|
2020
Q4 | $235K | Sell |
14,671
-3,095
| -17% | -$40.9K | ﹤0.01% | 2808 |
|
|
2020
Q3 | $220K | Buy |
17,766
+12,982
| +271% | +$153K | ﹤0.01% | 2723 |
|
|
2020
Q2 | $34.1K | Sell |
4,784
-19,906
| -81% | -$133K | ﹤0.01% | 3188 |
|
|
2020
Q1 | $134K | Sell |
24,690
-13,730
| -36% | -$123K | ﹤0.01% | 3066 |
|
|
2019
Q4 | $348K | Sell |
38,420
-6,795
| -15% | -$55.2K | ﹤0.01% | 2687 |
|
|
2019
Q3 | $325K | Buy |
45,215
+2,062
| +5% | +$14.8K | ﹤0.01% | 2459 |
|
|
2019
Q2 | $343K | Buy |
43,153
+19,840
| +85% | +$235K | ﹤0.01% | 2251 |
|
|
2019
Q1 | $293K | Buy |
23,313
+19,451
| +504% | +$308K | ﹤0.01% | 2460 |
|
|
2018
Q4 | $77K | Sell |
3,862
-11
| -0.3% | -$254 | ﹤0.01% | 2495 |
|
|
2018
Q3 | $110K | Buy |
3,873
+207
| +6% | +$4.94K | ﹤0.01% | 2687 |
|
|
2018
Q2 | $77.2K | Sell |
3,666
-8,922
| -71% | -$169K | ﹤0.01% | 2919 |
|
|
2018
Q1 | $179K | Sell |
12,588
-2,513
| -17% | -$36K | ﹤0.01% | 2852 |
|
|
2017
Q4 | $186K | Buy |
15,101
+8,980
| +147% | +$127K | ﹤0.01% | 2998 |
|
|
2017
Q3 | $109K | Buy |
6,121
+1,370
| +29% | +$28.2K | ﹤0.01% | 2733 |
|
|
2017
Q2 | $120K | Buy |
4,751
+4,232
| +815% | +$102K | ﹤0.01% | 2730 |
|
|
2017
Q1 | $11.6K | Sell |
519
-203
| -28% | -$3.9K | ﹤0.01% | 3148 |
|
|
2016
Q4 | $10.7K | Sell |
722
-671
| -48% | -$13.2K | ﹤0.01% | 3421 |
|
|
2016
Q3 | $34.3K | Buy |
1,393
+803
| +136% | +$18.8K | ﹤0.01% | 2608 |
|
|
2016
Q2 | $11.3K | Buy |
+590
| New | +$8.1K | ﹤0.01% | 2853 |
|
|
2016
Q1 | – | Sell |
-2,296
| Closed | -$27.8K | – | 2797 |
|
|
2015
Q4 | $27.8K | Sell |
2,296
-159
| -6% | -$2.34K | ﹤0.01% | 3160 |
|
|
2015
Q3 | $39.2K | Buy |
+2,455
| New | +$47.9K | ﹤0.01% | 3037 |
|
Other funds holding EVH
CCM
RF
EC
VCM
RSCM
BNP Paribas Financial Markets's EVH Position: Q1 2026 in Review
BNP Paribas Financial Markets increased its Evolent Health (EVH) stake by 64% in Q1 2026, buying an estimated $1.1M and bringing the position to 891,403 shares worth $2.03M. The position accounts for ﹤0.01% of the portfolio, ranked #2649.
BNP Paribas Financial Markets first reported a position in EVH in Q3 2015 and has held it in 42 quarters since. The position peaked at $5.96M in Q3 2022. 191 funds tracked by Wall St. Rank hold EVH as of Q1 2026.
- BNP Paribas Financial Markets held 891,403 shares of Evolent Health worth $2.03M as of Q1 2026.
- BNP Paribas Financial Markets bought 347,019 Evolent Health shares in Q1 2026, an estimated $1.1M.
- Evolent Health made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #2649 holding.
- BNP Paribas Financial Markets first reported a position in Evolent Health in Q3 2015 and has held it in 42 quarters since.
- BNP Paribas Financial Markets's Evolent Health position peaked at $5.96M in Q3 2022.
- 191 funds tracked by Wall St. Rank held Evolent Health as of Q1 2026.
Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.